Postmenopausal Osteoporosis Market, by Drug Class, by Route of Administration, by Distribution Channel, by Region - Size, Share, Outlook, and Opportunity Analysis, 2022

Description

Osteoporosis is a medical condition in which the bones become brittle and fragile due to decreased bone mass and bone mineral density, leading to frequent fragility fractures. Worldwide, one in three women over the age of 50 is at risk of developing osteoporosis. It could be due to hormonal changes or a lack of calcium and vitamin D. Along with increased incidences of fractures in older, postmenopausal women, osteoporosis may often lead to mobility loss and perhaps morbidity and death. A major reason for developing this disease and the associated bone loss in women is estrogen deficiency. Other important risk factors are genetics, advanced age, being underweight, smoking, alcohol abuse, etc. Ample intake of protein, calcium, and vitamin D may help prevent postmenopausal osteoporosis without pharmacologic means. Doctors also suggest regular physical activity and avoiding smoking and alcohol consumption to lower the risk. For premenopausal women (women naturally approaching menopause) and those with low bone density and other risk factors, estrogen and drugs are recommended for improved bone density and strength.

Market Dynamics

Increasing inorganic growth activities such as agreements among market players is expected to drive the growth of the global postmenopausal osteoporosis market over the forecast period. For instance, on June 10, 2021, Theramex UK Ltd, a global specialty pharmaceutical company announced a license and supply agreement with Enzene Biosciences Limited, a Biotechnology company for the registration and commercialization of Denosumab, an antiresorptive treatment for osteoporosis.

Key features of the study:

This report provides an in-depth analysis of the global postmenopausal osteoporosis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global postmenopausal osteoporosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global postmenopausal osteoporosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global postmenopausal osteoporosis market

Detailed Segmentation:

Global Postmenopausal Osteoporosis Market, By Drug Class:
- Bisphosphonates
- Selective Estrogen Receptor Modulators (SERMs)
- RANK Ligand Inhibitors
- Anabolic Class
- Calcium Metabolism Modifiers
- Others (Calcitonin, Denosumab, among Others)
Global Postmenopausal Osteoporosis Market, By Route of Administration:
- Oral
- Intravenous Route
- Subcutaneous
Global Postmenopausal Osteoporosis Market By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Postmenopausal Osteoporosis Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Pfizer Inc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- F.Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris Inc.)
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd
- Ligand Pharmaceuticals Incorporated
- Paras Biopharmaceuticals Finland Oy
- Eli Lilly and Company
- TRANSCENTA HOLDING
- Amgen
- Gedeon Richter Plc.
- Enzene Biosciences
- Samsung BioepisL Radius Health, Inc.
- Alvotech
- AryoGen Pharmed

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI5479

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
Product Launches
Merger, Acquisition, Collaboration
Regulatory Guideline and Compliances
Key Developments
PEST Analysis
Technology Landscape
PORTER's Analysis
Pricing Analysis (2021)

4. Global Postmenopausal Osteoporosis Market - Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Postmenopausal Osteoporosis Market, By Drug Class, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Selective Estrogen Receptor Modulators (SERMs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
RANK Ligand Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Anabolic Class
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Calcium Metabolism Modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others (Calcitonin, Denosumab, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Postmenopausal Osteoporosis Market, By Route of Administration, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Intravenous Route
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Postmenopausal Osteoporosis Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segments Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Postmenopausal Osteoporosis Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Pfizer Inc. *
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche Ltd
Mylan N.V. (Viatris Inc.)
Fresenius Kabi AG
Hikma Pharmaceuticals PLC
Novartis AG
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Sun Pharmaceutical Industries Ltd
Ligand Pharmaceuticals Incorporated
Paras Biopharmaceuticals Finland Oy
Eli Lilly and Company
TRANSCENTA HOLDING
Amgen
Gedeon Richter Plc.
Enzene Biosciences
Samsung BioepisL Radius Health, Inc.
Alvotech
AryoGen Pharmed

10. Section

Research Methodology
About Us

Postmenopausal Osteoporosis Market, by Drug Class, by Route of Administration, by Distribution Channel, by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030